Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease

David Charles, Peter E. Konrad, Joseph S. Neimat, Anna L. Molinari, Michael G. Tramontana, Stuart G. Finder, Chandler E. Gill, Mark J. Bliton, Chris Kao, Fenna T. Phibbs, Peter Hedera, Ronald M. Salomon, Kevin R. Cannard, Lily Wang, Yanna Song, Thomas L. Davis

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson's disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. Methods: Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50-75, on medication ≥6 months but ≤4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n=15) or DBS+ODT (n=15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. Results: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. Medication requirements in the DBS + ODT group were lower at all time points with a maximal difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS+ODT group suffered serious adverse events; remaining adverse events were mild or transient. Conclusions: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.

Original languageEnglish (US)
Pages (from-to)731-737
Number of pages7
JournalParkinsonism and Related Disorders
Volume20
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Subthalamic Nucleus
Deep Brain Stimulation
Parkinson Disease
Drug Therapy
Safety
Dyskinesias
Levodopa
Therapeutics
Multicenter Studies

Keywords

  • Deep brain stimulation
  • Parkinson's disease
  • Subthalamic nucleus

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Charles, D., Konrad, P. E., Neimat, J. S., Molinari, A. L., Tramontana, M. G., Finder, S. G., ... Davis, T. L. (2014). Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism and Related Disorders, 20(7), 731-737. https://doi.org/10.1016/j.parkreldis.2014.03.019

Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. / Charles, David; Konrad, Peter E.; Neimat, Joseph S.; Molinari, Anna L.; Tramontana, Michael G.; Finder, Stuart G.; Gill, Chandler E.; Bliton, Mark J.; Kao, Chris; Phibbs, Fenna T.; Hedera, Peter; Salomon, Ronald M.; Cannard, Kevin R.; Wang, Lily; Song, Yanna; Davis, Thomas L.

In: Parkinsonism and Related Disorders, Vol. 20, No. 7, 01.01.2014, p. 731-737.

Research output: Contribution to journalArticle

Charles, D, Konrad, PE, Neimat, JS, Molinari, AL, Tramontana, MG, Finder, SG, Gill, CE, Bliton, MJ, Kao, C, Phibbs, FT, Hedera, P, Salomon, RM, Cannard, KR, Wang, L, Song, Y & Davis, TL 2014, 'Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease', Parkinsonism and Related Disorders, vol. 20, no. 7, pp. 731-737. https://doi.org/10.1016/j.parkreldis.2014.03.019
Charles D, Konrad PE, Neimat JS, Molinari AL, Tramontana MG, Finder SG et al. Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism and Related Disorders. 2014 Jan 1;20(7):731-737. https://doi.org/10.1016/j.parkreldis.2014.03.019
Charles, David ; Konrad, Peter E. ; Neimat, Joseph S. ; Molinari, Anna L. ; Tramontana, Michael G. ; Finder, Stuart G. ; Gill, Chandler E. ; Bliton, Mark J. ; Kao, Chris ; Phibbs, Fenna T. ; Hedera, Peter ; Salomon, Ronald M. ; Cannard, Kevin R. ; Wang, Lily ; Song, Yanna ; Davis, Thomas L. / Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. In: Parkinsonism and Related Disorders. 2014 ; Vol. 20, No. 7. pp. 731-737.
@article{13bc6eabb17a4816840299e9d591a870,
title = "Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease",
abstract = "Background: Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson's disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. Methods: Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50-75, on medication ≥6 months but ≤4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n=15) or DBS+ODT (n=15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. Results: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. Medication requirements in the DBS + ODT group were lower at all time points with a maximal difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS+ODT group suffered serious adverse events; remaining adverse events were mild or transient. Conclusions: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.",
keywords = "Deep brain stimulation, Parkinson's disease, Subthalamic nucleus",
author = "David Charles and Konrad, {Peter E.} and Neimat, {Joseph S.} and Molinari, {Anna L.} and Tramontana, {Michael G.} and Finder, {Stuart G.} and Gill, {Chandler E.} and Bliton, {Mark J.} and Chris Kao and Phibbs, {Fenna T.} and Peter Hedera and Salomon, {Ronald M.} and Cannard, {Kevin R.} and Lily Wang and Yanna Song and Davis, {Thomas L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.parkreldis.2014.03.019",
language = "English (US)",
volume = "20",
pages = "731--737",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease

AU - Charles, David

AU - Konrad, Peter E.

AU - Neimat, Joseph S.

AU - Molinari, Anna L.

AU - Tramontana, Michael G.

AU - Finder, Stuart G.

AU - Gill, Chandler E.

AU - Bliton, Mark J.

AU - Kao, Chris

AU - Phibbs, Fenna T.

AU - Hedera, Peter

AU - Salomon, Ronald M.

AU - Cannard, Kevin R.

AU - Wang, Lily

AU - Song, Yanna

AU - Davis, Thomas L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson's disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. Methods: Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50-75, on medication ≥6 months but ≤4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n=15) or DBS+ODT (n=15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. Results: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. Medication requirements in the DBS + ODT group were lower at all time points with a maximal difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS+ODT group suffered serious adverse events; remaining adverse events were mild or transient. Conclusions: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.

AB - Background: Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson's disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. Methods: Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50-75, on medication ≥6 months but ≤4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n=15) or DBS+ODT (n=15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. Results: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. Medication requirements in the DBS + ODT group were lower at all time points with a maximal difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS+ODT group suffered serious adverse events; remaining adverse events were mild or transient. Conclusions: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD.

KW - Deep brain stimulation

KW - Parkinson's disease

KW - Subthalamic nucleus

UR - http://www.scopus.com/inward/record.url?scp=84902304063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902304063&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2014.03.019

DO - 10.1016/j.parkreldis.2014.03.019

M3 - Article

VL - 20

SP - 731

EP - 737

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 7

ER -